Table 3.
The comparison between cases with improvement of spontaneous bowel movements and cases without it.
| With improved bowel movements (n = 77) |
Without improved bowel movement (n = 27) |
p value | |
|---|---|---|---|
| Gender, n (%) | |||
| Male | 33 (42.9) | 11 (40.7) | 0.85 |
| Female | 44 (57.1) | 16 (59.3) | |
| Age, n (%) | |||
| ≤74 | 43 (55.8) | 12 (44.4) | 0.31 |
| ≥75 | 34 (48.1) | 15 (55.6) | |
| Laxative combination, n (%) | 43 (44.8) | 17 (63.0) | 0.52 |
| Irritant laxative combination, n (%) | 21 (27.3) | 6 (22.2) | 0.61 |
| Elobixibat dose, n (%) | |||
| 5 mg | 18 (23.4) | 4 (14.8) | 0.53 |
| 10 mg | 51 (66.2) | 21 (77.8) | |
| 15 mg | 8 (10.4) | 2 (7.4) | |
| Underlying disease, n (%) | |||
| Dyslipidemia | 26 (33.8) | 9 (33.3) | 0.97 |
| Diabetes | 16 (20.8) | 5 (18.5) | 0.80 |
| Hepatic disorder | 3 (3.9) | 2 (7.4) | 0.46 |
| Hypothyroidism | 4 (5.2) | 0 (0) | 0.23 |
| Parkinson's disease | 3 (3.9) | 0 (0) | 0.30 |
| Concomitant medication, n (%) | |||
| Antacids | 31 (40.3) | 11 (40.7) | 0.97 |
| Antidepressants | 7 (9.1) | 4 (14.8) | 0.41 |
| Calcium antagonists | 8 (10.4) | 2 (7.4) | 0.65 |
| Parkinson's disease drugs | 3 (3.9) | 0 (0) | 0.30 |
| Ursodeoxycholic acid | 2 (2.6) | 0 (0) | 0.40 |